Inhibition of MSTN is considered as a promising therapy for muscle-wasting disorders, including Duchenne muscular dystrophy (DMD), a lethal and common form of muscular dystrophy affecting ∼1 in 5000 newborn boys worldwide (10, 11). The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.